Commentary: SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Carta Acesso aberto Revisado por pares

Commentary: SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

2020; Frontiers Media; Volume: 10; Linguagem: Inglês

10.3389/fonc.2020.01448

ISSN

2234-943X

Autores

Alexandra Lindsey Djomkam Zune, Charles Ochieng’ Olwal, Theodore Beyeme Sala, Lily Paemka,

Tópico(s)

COVID-19 Impact on Reproduction

Resumo

GENERAL COMMENTARY article Front. Oncol., 19 August 2020Sec. Molecular and Cellular Oncology Volume 10 - 2020 | https://doi.org/10.3389/fonc.2020.01448

Ver no editor

Altmetric

PlumX

Entrar

Lembrar minha senha

Receber meu e-mail de confirmação

Commentary: SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor